Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333916 | 0.91 | ALDH1A1 (0.46) | GRM5ALDH1A1HPGDSMN1; SMN2CYP2C19 | |
| SCHEMBL4329832 | 0.85 | GRM5 (0.67) | GRM5 | |
| SCHEMBL4342428 | 0.82 | GRM5 (0.57) | GRM5ALDH1A1CYP2C19HTT | |
| SCHEMBL4335449 | 0.82 | GRM5 (0.59) | GRM5ALDH1A1CYP2C19HTT | |
| SCHEMBL4326741 | 0.81 | GRM5 (0.58) | GRM5ALDH1A1CYP2C19HTT | |
| SCHEMBL4343720 | 0.81 | GRM5 (0.48) | GRM5ALDH1A1HPGDCYP2C19HTT | |
| SCHEMBL4332896 | 0.81 | GRM5 (0.48) | GRM5ALDH1A1CYP2C19HTT | |
| SCHEMBL4325545 | 0.81 | GRM5 (0.48) | GRM5ALDH1A1CYP2C19HTT | |
| SCHEMBL4635772 | 0.81 | GRM5 (0.41) | GRM5 | |
| SCHEMBL4327921 | 0.81 | GRM5 (0.63) | GRM5ALDH1A1HPGDSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | claimed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | claimed |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-12-29 | — | — | US | claimed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1931635-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | GRM5 2/4885ALDH1A1 2587/4885HPGD 872/4885 |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | GRM5 2/4885ALDH1A1 3100/4885HPGD 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.